THE APPROPRIATENESS OF ANTITHROMBOTIC THERAPY IN PATIENTS WITH NON-VALVULAR ATRIAL FIBRILLATION IN REAL CLINICAL PRACTICE
https://doi.org/10.21518/2079-701X-2016-13-85-88
Abstract
The article evaluates the risk of thromboembolic complications and appropriateness of oral anticoagulants (OAC) in patients with non-valvular atrial fibrillation (AF) upon admission to inpatient treatment at the Tyumen Cardiology Center in 2014. The majority of patients with non- valvular AF, which is 82% of the total number of patients admitted to the hospital, were referred to the high risk group for thromboembolic events (≥ 2 points according to HA2DS2VASc). Before hospitalization, 39.4% of high-risk patients were taking OAC, the majority receiving warfarin. The therapeutic INR range at admission was registered in 30.8% of patients treated with warfarin. 11.1% of high-risk patients received new OAC. Thus, the nticoagulant therapy could be appropriate in 205 patients (19.8% of the high-risk group). There was a relationship between OAC treatment and the risks according to CHADS2 and HAS-BLED, but not CHA2 DS2VASc. OAC were more frequently administered by patients with persistent AF. The article demonstrates the need for a comprehensive educational and organizational initiative aimed at ensuring antithrombotic therapy which corresponds to the current clinical guidelines for patients with non-valvular AF.
About the Authors
A. Y. RYCHKOV
Branch of Cardiology Research Institute «Tyumen Cardiology Center»
Russian Federation
MD
Russian Federation
MD
N. Y. KHORKOVA
Branch of Cardiology Research Institute «Tyumen Cardiology Center»
Russian Federation
PhD in medicine
Russian Federation
PhD in medicine
A. V. MINULINA
Branch of Cardiology Research Institute «Tyumen Cardiology Center»
Russian Federation
Russian Federation
References
1. Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation as an independent risk factor for stroke: the Framingham Study. Stroke, 1991, 22(8): 983-988.
2. Диагностика и лечение фибрилляции предсердий, рекомендации РКО, ВНОА и АССХ. Российский кардиологический журнал, 2014, 4(102), приложение 3. / Diagnosis and treatment of atrial fibrillation, recommendations of the Russian Society of Cardiology, Russian Society of Arrhythmology and Association of Cardiovascular Surgeons of Russia. Rossiyskiy Kardiologicheskiy Zhurnal, 2014, 4(102), supplement 3.
3. CardioPulse Articles / Anticoagulants reduce risk of death in atrial fibrillation patients by 38%. Eur Heart J, 2016, 37: 860-867.
4. Camm AJ, Pinto FJ, Hankey GJ, Andreotti F, Hobbs FD. Writing committee of the action for stroke prevention alliance. Non-vitamin K antagonist oral anticoagulants and atrial fibrillation guidelines in practice: barriers to and strategies for optimal implementation. Europace, 2015, 17(7): 1007-1017.
5. Лукьянов М.М., Бойцов С.А., Якушин C.С., Марцевич С.Ю., Воробьев А.Н., Загребельный А.В. и др. Диагностика, лечение, сочетанная сердечно-сосудистая патология и сопутствующие заболевания у больных с диагнозом «фибрилляция предсердий» в условиях реальной амбулаторно-поликлинической практики (по данным РЕгистра КардиоВАскулярных ЗАболе ваний РЕКВАЗА). Рациональная фармакотерапия в кардиологии, 2014, 10(4): 366-377. / Lukyanov M.M., Boitsov S.A., Yakushin S.S., Martsevich S.Y., Vorob’yov A.N., Zagrebel’niy A.V. et al. Diagnosis, treatment, concomitant cardiovascular disease and comorbidities in patients diagnosed with «atrial fibrillation» in actual outpatient practice (according to the register of cardiovascular diseases REKVAZA). Ratsionalnaya Farmakoterapiya v Kardiologii, 2014, 10(4): 366-377.
6. Линчак Р.М., Компаниец О.Г., Недбайкинз А.М., Ком ков Д.С., Юсоваз И.А. Каковы реалии назначения и контроля антитромботической терапии при фибрилляции предсердий в амбулаторной практике? Кардиология, 2015, 55(6): 34-39. / Linchak R.M., Kompaniets O.G., Nedbaykinz A.M., Komkov D.S., Yuso vaz I.A. What are the realities of prescription and moni toring of antithrombotic therapy in atrial fibrillation in outpatient practice? Kardiologiya, 2015, 55 (6): 34-39.
7. Kakkar AK, Mueller I, Bassand JP, Fitzmaurice DA, Goldhaber SZ, Goto S, Haas S et al. GARFIELD Registry Investigators. Risk profiles and antithrombotic treatment of patients newly diagnosed with atrial fibrillation at risk of stroke: perspectives from the international, observational, prospective GARFIELD registry. PLoS One, 2013, 8(5): e63479.
8. Kirchhof P, Ammentorp B, Darius H, De Caterina R, Le Heuzey JY, Schilling RJ et al. Management of atrial fibrillation in seven European countries after the publication of the 2010 ESC Guidelines on atrial fibrillation: primary results of the PREven tion oF thromboemolic events – European Registry in Atrial Fibrillation (PREFER in AF). Europace, 2014, 16: 6-14.
9. Camm AJ, Amarenco P, Haas S, Hess S, Kirchhof P, Kuhls S et al. XANTUS Investigators. XANTUS: a real-world, prospective, observational study of patients treated with rivaroxaban for stroke prevention in atrial fibrillation. Eur Heart J, 2016, 37(14): 1145-1153.
10. Chai-Adisaksopha C, Hillis C, Isayama T, Lim W, Iorio A, Crowther M. Mortality outcomes in patients receiving direct oral anticoagulants: a systematic review and meta-analysis of randomized controlled trials. J Thromb Haemost, 2015, 13(11): 2012-2020.
11. An J, Niu F, Lang DT, Jazdzewski KP, Le PT, Rashid N, Meissner B, Mendes R, Dills DG, Aranda G, Bruno A. Stroke and Bleeding Risk Associated With Antithrombotic Therapy for Patients With Nonvalvular Atrial Fibrillation in Clinical Practice. J Am Heart Assoc, 2015, 4(7). pii: e001921.
12. De Caterina R, Husted S, Wallentin L, Andreotti F, Arnesen H, Bachmann F et al. Vitamin K antagonists in heart disease: current status and perspectives (Section III). Position paper of the ESC Working Group on Thrombosis – Task Force on Anticoagulants in Heart Disease. Thromb Haemost, 2013, 110(6): 1087-107.
13. Björck F, Renlund H, Lip GYH, Wester P, Svensson PJ, Själander A. Outcomes in a warfarin- treated population with atrial fibrillation. JAMA Cardiol, 2016, 1(2): 172-180.
14. Janzic A, Kos M. Cost effectiveness of novel oral anticoagulants for stroke prevention in atrial fibrillation depending on the quality of warfarin anticoagulation control. harmacoeconomics, 2015, 33(4): 395-408.
15. Hylek EM, Skates SJ, Sheehan MA, Singer DE. An analysis of the lowest effective intensity of prophylactic anticoagulation for patients with nonrheumatic atrial fibrillation. N Engl J Med, 1996, 335(8): 540-546.
16. Hylek EM, Go AS, Chang Y, Jensvold NG, Henault LE, Selby JV et al. Effect of intensity of oral anticoagulation on stroke severity and mortality in atrial fibrillation. N Engl J Med, 2003, 349(11): 1019-1026.
17. Ganesan AN, Chew DP, Hartshorne T, Selvanayagam JB, Aylward PE, Sanders P, McGavigan AD. The impact of atrial fibrillation type on the risk of thromboembolism, mortality, and bleeding: a systematic review and meta-analysis. European Heart Journal, 2016, 37: 1591-1602.
18. White HD, Gruber M, Feyzi J et al. Comparison of outcomes among patients randomized to warfarin therapy according to anticoagulant control: results from SPORTIF III and V. Arch Intern Med, 2007, 167: 239-245.
19. Witt DM, Delate T, Clark NP et al. Outcomes and predictors of very stable INR control during chronic anticoagulation therapy. Blood, 2007, 114: 952-956.
Review
For citations:
RYCHKOV AY, KHORKOVA NY, MINULINA AV. THE APPROPRIATENESS OF ANTITHROMBOTIC THERAPY IN PATIENTS WITH NON-VALVULAR ATRIAL FIBRILLATION IN REAL CLINICAL PRACTICE. Meditsinskiy sovet = Medical Council. 2016;(13):85-88. (In Russ.) https://doi.org/10.21518/2079-701X-2016-13-85-88
Views:
690
Email this article 